Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
Related Tickers: APVO
TL;DR
APVO filed an 8-K, standard procedure, no new info.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on March 7, 2024, to report other events and financial statements. The filing does not contain specific details about new material events or financial figures beyond standard reporting requirements.
Why It Matters
This 8-K filing indicates that Aptevo Therapeutics Inc. is fulfilling its regulatory reporting obligations with the SEC, but it does not disclose new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for reporting purposes and does not contain any new material events, financial updates, or strategic changes that would inherently increase risk.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- March 07, 2024 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the purpose of this 8-K filing for Aptevo Therapeutics Inc.?
The 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of March 7, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 07, 2024.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The address is 2401 4th Avenue Suite 1050, Seattle, Washington 98121.
What is the company's telephone number?
The company's telephone number is (206) 838-0500.
Does this filing disclose any new material events or financial information?
Based on the provided text, this filing appears to be a routine report and does not explicitly detail new material events or specific financial figures beyond standard reporting categories.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-03-07 08:56:23
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20240307.htm (8-K) — 38KB
- apvo-ex99_1.htm (EX-99.1) — 35KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-027613.txt ( ) — 200KB
- apvo-20240307.xsd (EX-101.SCH) — 25KB
- apvo-20240307_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On March 7, 2024, Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics Inc. (the "Company") issued a press release today announcing positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. aptevo therapeutics inc Date: March 7, 2024 By: /s/ Marvin L. White President and Chief Executive Officer